Changes in tumor size by RECIST correlate with survival

June 13, 2012
Changes in tumor size by RECIST correlate with survival
RECIST categories used to quantify tumor changes during exposure to anticancer therapies correlate well with overall survival but reflect a more linear continuum without clear inflection points, according to a study published online June 11 in the Journal of Clinical Oncology.

(HealthDay) -- RECIST categories used to quantify tumor changes during exposure to anticancer therapies correlate well with overall survival (OS) but reflect a more linear continuum without clear inflection points, according to a study published online June 11 in the Journal of Clinical Oncology.

Rajul K. Jain, M.D., of the University of Texas MD Anderson Cancer Center in Houston, and colleagues studied the correlation between OS and response, as quantified by RECIST, in 570 participants of 24 phase I oncology trials conducted between October 2004 and May 2009.

The researchers found that 468 of the participants had quantifiable changes in tumor size. Change in tumor size during exposure to anticancer agents, as quantified by RECIST, correlated well with OS in a near-linear fashion without clear inflection points. Residual analyses were used to confirm the association.

"RECIST quantification of response correlates with survival, validating RECIST's use in phase I trials. However, the lack of apparent boundary values in the relationship between change in and OS demonstrates the arbitrary nature of the complete response/partial response/stable disease/ categories and questions emphasis placed on this categorization scheme," the authors write. "Describing tumor responses as a continuous variable may be more informative than reporting categoric responses when evaluating novel ."

One author disclosed a financial tie to Amgen.

Explore further: Pancreatectomy OK without downstaging from therapy

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Pancreatectomy OK without downstaging from therapy

May 25, 2012
(HealthDay) -- Pancreatectomy improves median survival in pancreatic cancer patients even when presurgical neoadjuvant therapy does not lead to radiographic downstaging of tumors, according to a study published online May ...

Chemotherapy's effect on overall survival seems to increase based on tumor size

May 15, 2012
The most recent research released in June's Journal of Thoracic Oncology indicates there might be a positive correlation between tumor size and adjuvant platinum based chemotherapy in surgically resected patients with node ...

High survival with surgery in low-risk neuroblastoma

April 25, 2012
(HealthDay) -- Surgery alone results in high five-year event-free and overall survival (EFS and OS) rates for patients with low-risk stage 2a and 2b neuroblastoma (NBL), according to research published online April 23 in ...

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.